TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

Reuters

2025/12/04

TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026

TScan Therapeutics Inc. announced it will host a virtual key opinion leader $(KOL)$ event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2588702140"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588702140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588702140?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588702140","market":"fut","top_or_hot":-1,"title":"TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL7ln8DZ:1","article_id":"2588702140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588702140","pubTimestamp":1764795913,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TScan Therapeutics Inc. announced it will host a virtual key opinion leader  event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology  Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","TCRX":"Tscan Therapeutics, Inc.","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"TScan Therapeutics公布更新的Alloha 1期试验数据和2026年关键研究计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":0.9,"NDAQ":0.9},"content_text":"TScan Therapeutics Announces Updated ALLOHA Phase 1 Trial Data and Plans for Pivotal Study in 2026\n    \n\n        TScan Therapeutics Inc. announced it will host a virtual key opinion leader $(KOL)$ event to discuss updated clinical data from the ALLOHA Phase 1 trial evaluating TSC-101 in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation. The event will feature a review of two-year relapse data on initial patients from the ongoing trial, as well as an overview of the company's newly implemented commercial-ready manufacturing process for TSC-101. This updated process will also be used in an upcoming pivotal trial scheduled to begin in the second quarter of 2026. Clinical results are being presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition. The company will also discuss the unmet medical need and potential market opportunity for TSC-101 and related product candidates during the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596376-en) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}